BMG PHARMA SPA
BMG Pharma is involved in the development of new healthcare products in the areas of oral care, dermatology including aesthetics, anaemia, osteoarthritis & cancer supportive care.
The company has created a strong portfolio of intellectual property which it has developed into a number of products that have been partnered with companies around the world.
The company recently merged with Sigea,an Italian company with expertise in targeted functional ingredients development currently focused on modified sodium hyaluronate for application in a number of therapeutic areas including dermatology and oral care. This merger will allow BMG to accelerate the development of a number of new products to complement its portfolio.
Mr Paul PhullCOO
Boehringer Ingelheim Corporate Center GmbH
Mr Juergen BeckHead of Strategic Transactions & Alliance Management
CHIESI FARMACEUTICI SPA
Dr Mario MaruzziHead of Transactions Europe & Emerging Countries-Global Corporate Development
Elena TommesaniHead of BD& Licensing - Chiesi Italy
Marco BarnaboBusiness Development & Licensing Manager
Chugai Pharma Europe Ltd.
Chugai Pharma Europe Ltd. is seeking for in-licensing and partnering opportunities for its European key territories in UK, Germany and France. We strive to build our business model on existing partnerships in oncology/hematology and rheumatology as well as to grow as a organization with strong commercialization expertise, broad market access and pricing knowledge and valuable experience in medical advocacy and KOL Management.
We look forward to meeting you in Montreux,
Ryo ishimura and Florian Streckert
Mr Florian StreckertBusiness Development Manager
Mr Ryo IshimuraMarketing Manager
Circassia: specialty respiratory pharmaceutical and medical device company
Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.
We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA. We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.
In-licensing or acquisition targets
We are actively looking for new pharmaceutical products/devices in US, China and Europe. Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team. We would also consider products that share a common physician call point.
Out licensing opportunities
We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.
Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.